10-K: Inhibikase Therapeutics Pauses Parkinson's Program, Focuses on PAH Treatment After $110M Raise

Inhibikase Therapeutics shifts strategic focus to its IKT-001 program for Pulmonary Arterial Hypertension (PAH) after pausing development of its Parkinson's disease treatment, supported by recent $110 million private placement.

Summary

• Inhibikase Therapeutics is prioritizing its IKT-001 program for PAH after deciding to pause further development of risvodetinib for Parkinson's disease.
• The company completed the Phase 2 201 Trial for risvodetinib in October 2024 and reported results in January 2025.
• IKT-001, a prodrug of imatinib mesylate, is designed to improve oral absorption and reduce GI side effects.
• A bioequivalence study (501 trial) established that 300 mg of IKT-001 is bioequivalent to 230 mg of imatinib mesylate, and 500 mg of IKT-001 is bioequivalent to 383 mg of imatinib mesylate.
• In January 2024, the company met with the FDA to discuss the path to approval for IKT-001, with the FDA suggesting the 505(b)(2) pathway is appropriate.
• The FDA requested a comparative cell-culture study of the hERG ion channel, which showed neither IKT-001 nor imatinib mesylate were inhibitors.
• An IND was filed with the FDA on August 9, 2024, and a Phase 2b trial was cleared to initiate on September 9, 2024.
• A private placement in October 2024 raised approximately $110 million to support the IKT-001 program.
• The company plans to apply for Orphan Drug Designation for IKT-001 in PAH.
• The global PAH market was valued at $7.66 billion in 2023 and is estimated to grow at a CAGR of 5.4% between 2024 and 2030.
• In February 2025, Mark Iwicki succeeded Dr. Milton H. Werner as CEO, and Amit Munshi succeeded Roberto Bellini as Chairman of the board.
• The company acquired CorHepta Pharmaceuticals, Inc. in February 2025 for $15.0 million, issuing 4,979,101 shares of Common Stock to CorHepta's former stockholders.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The company is focusing on a promising program (IKT-001 for PAH) and has raised significant capital. However, it has also paused development of another program (risvodetinib) and has a history of net losses. The sentiment is neutral to slightly positive.

Positives

• IKT-001 has shown a 3.4-fold higher no-observed-adverse effect level (NOAEL) relative to imatinib in non-human primates, suggesting reduced side effects.
• The FDA confirmed that IKT-001 would be viewed as a New Molecular Entity (NME), potentially granting market exclusivity upon approval.
• The company has patent protection in the United States until 2033 for IKT-001, with potential extensions to 2045.
• The company has secured a number of grants from the United States Federal Government through the NIH totaling $10,053,365 since 2009.
• The company has received one contract from the Department of Defense (DoD), totaling $7,129,614, to develop so-called Medical Counter Measures (MCMs).

Negatives

• The company decided to pause further development of risvodetinib as we focus our resources on advancing lead program IKT-001 in PAH.
• The aggregate market value of the common stock held by non-affiliates of the Registrant on June 28, 2024 was $7.7 million.
• The company has incurred net losses since its inception, including net losses of $27,519,886 and $19,028,883 for the years ended December 31, 2024 and 2023, respectively.
• The company has an accumulated deficit of $94,420,611 as of December 31, 2024.

Risks

• The company is a clinical-stage drug development company with limited resources and no products approved for commercial sale.
• The company may be unable to successfully raise additional capital, which could limit future clinical trials and product development.
• Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
• The company has incurred significant net losses since its inception and anticipates that it will continue to incur net losses for the foreseeable future.
• The company's business is highly dependent on the success of its initial product candidates targeting neurodegenerative, cardiopulmonary and oncological diseases.
• The company currently contracts with various research institutions to perform the research and development activities needed to develop our products, and if we ever choose to or need to find alternative research institutions, we may not be able to do so at all or, if we are able to do so, it may be costly and may cause significant delays in the development and commercialization of our products.
• The company may encounter substantial delays in its current and planned clinical trials, or may not be able to conduct or complete its clinical trials on the timelines we expect, if at all.
• The manufacture of the company's product candidates is complex and difficulties may be encountered in production.
• If the company is unable to obtain and maintain patent protection for any product candidates it develops, its competitors could develop and commercialize products or technology similar or identical to ours, and its ability to successfully commercialize any product candidates it may develop, and its technology may be adversely affected.

Future Outlook

The company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in PAH and for general corporate purposes. The company expects to seek additional funds in the future through equity or debt financings, or strategic alliances with third parties, either alone or in combination with equity financings to complete its product development initiatives.

Management Comments

• Mark Iwicki succeeds Dr. Milton H. Werner, founder of Inhibikase, as our Chief Executive Officer.
• Amit Munshi succeeds Roberto Bellini as Chairman of our board of directors and will continue to serve on our board of directors.

Industry Context

The pharmaceutical industries, including in the PAH disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property. The company faces substantial competition from many different sources, including large and specialty pharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions.

Comparison to Industry Standards

• Companies currently marketing products for PAH include large companies with significant financial resources, that include but are not limited to GlaxoSmithKline, Johnson and Johnson, United Therapeutics, Gilead Sciences, and Merck and Co.
• Companies currently developing products in PAH are both large companies with significant financial resources as wells as smaller companies and include but are not limited to Merck and Co., Apollo Therapeutics, Novartis Pharmaceuticals, Pfizer, Gossamer Bio, and Insmed, Inc.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if IKT-001 is successful, but also risk due to the company's financial situation and the uncertainty of drug development.
• Employees: Changes in leadership and strategic focus may impact job security and opportunities.
• Patients: Potential for new treatment options for PAH.
• Creditors: Risk of default if the company is unable to raise additional capital.

Next Steps

• Initiate a Phase 2b trial in PAH with IKT-001.
• Apply for Orphan Drug Designation (ODD) for IKT-001 in PAH.
• Consider strategic options for the risvodetinib program.

Key Dates

Keywords

IKT-001, Pulmonary Arterial Hypertension, PAH, Risvodetinib, Parkinson's disease, Clinical trial, FDA, Bioequivalence, Pharmaceutical, Drug development